Pasithea Therapeutics's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Pasithea Therapeutics's ROI in the second quarter of 2026?
Pasithea Therapeutics Corp recorded a cumulative net loss of $-22 million during 12 months ending in the second quarter of 2026, resulting in a negative return on investment (ROI) of -45.88%.

Within the Healthcare sector 117 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 3480 to 3671.

Definition and Formula of Return on Investment

Select the Comparisons :

None ▼

Select the Ratio:

Return on Investment ROI▼

None ▼

Return on Investment ROI▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Investment	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Jun 30 2025) II. Quarter	(Mar 31 2025) I. Quarter
Y / Y Investment Change TTM	199 %	119.35 %	32.7 %	-36.8 %	-44.3 %
Y / Y Net Income Change TTM	-	-	-	-	-
Investment (TTM) in Millions	50	55	71	15	13
Return On Investment (TTM)	-45.88 %	-52.27 %	-72.36 %	-89.15 %	-81.13 %
KTTA's Overall Ranking	# 3671	# 3480	# 0	# 3810	#
Seq. Investment Change TTM	23.57 %	34.68 %	87.11 %	-3.98 %	-9.35 %
Seq. Net Income Change TTM	-	-	-	-	-
Net Income (TTM) in Millions	-22	-20	-21	-14	-13

KTTA Company Profile >> Back to KTTA Roi Comparisons >> See Annual KTTA Return On Investment

Return On Investment KTTA's Ranking
Within:	No.
Industry	# 32
Sector	# 118
Overall	# 3671

Return On Investment Statistics
High	Average	Low
-9.95 %	-50.64 %	-89.15 %
(Jun 30 2022)		(Jun 30 2025)

News about Pasithea Therapeutics Corp Return on Investment ROI

Pasithea Therapeutics Appoints Dr. Rebecca Brown to Scientific Advisory Board and Completes Successful Tender Offer Acquisition, Building Investor Confidence and Enhancing Growth Potential,

September 3, 2024

Pasithea Therapeutics, a leading biotech company, has recently appointed Dr. Rebecca Brown to its Scientific Advisory Board. Dr. Brown, an expert in Neurofibromatosis and Director at Mount Sinai, will be instrumental in providing her expertise to aid in the development of PAS-004. This appointment highlights Pasithea Therapeutics commitment to advancing medical research and finding innovative treatments for patients.
In addition to this exciting appointment, Pasithea Therapeutics also reported a cumulative net loss of $-15 million during the 12 months ending in the second quarter of 2024, resulting in a negative return on investment (ROI) of -49.28%. This financial performance indicates challenges faced by the company in generating profits and creating shareholder value.

Pasithea Therapeutics Reports Positive Pre-IND Meeting Outcome but Faces Financial Struggles with a Negative ROI

November 29, 2023

Pasithea Therapeutics Faces Financial Challenges Amid Positive Clinical Development Outcome
Pasithea Therapeutics Corp, a healthcare company specializing in MEK inhibitor development, recently announced the outcome of its Pre-Investigational New Drug (Pre-IND) meeting with the U.S. Food and Drug Administration (FDA) for the clinical development of its PAS-004 drug. Despite positive progress in drug development, the company s financial performance has been concerning, as it recorded a cumulative net loss of $16 million during the 12 months ending in the third quarter of 2023. This resulted in a negative return on investment (ROI) of -43.82%.
Within the healthcare sector, Pasithea Therapeutics falls behind 398 other companies in terms of ROI. This financial setback raises questions about the company s ability to attract investors and support its ongoing research and development efforts.

Financial Statements
Pasithea Therapeutics's II. Quarter Investments	$ 50 Millions	KTTA's Balance sheet
Pasithea Therapeutics's II. Quarter Income	$ -5 Millions	Quarterly KTTA's Income Statement
KTTA's Income by Division		See KTTA's Income by Division

KTTA Annual Return On Investment	(Sep 30 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021
Total Investments in Millions	12	15	31	43	51
Y / Y Investment Growth	-18.01 %	-51.81 %	-27.27 %	-17.08 %	-
Net Income in Millions	-3	-14	-16	-14	-2
Y / Y Net Income Growth	-	-	-	-	-
Annual Return On Investment	-24.79 %	-93.04 %	-51.47 %	-32.68 %	-4.23 %

Annual Roi Comment

Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
KTTA's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for KTTA's Competitors
Subscribers only: Roi for Pasithea Therapeutics's Suppliers
Subscribers only: Return On Investment for KTTA's Customers

Other Ratios
KTTA's Roa	KTTA's Inventory Turnover Ratio	KTTA's Growth Rates	KTTA's Dividend Statistics
	KTTA's Profitability Ratios	KTTA's Asset Turnover Ratio	KTTA's Dividend Growth
KTTA's Roe	KTTA's Valuation Ratios	KTTA's Financial Strength Ratios	KTTA's Dividend Payout Ratio

Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector

ROI

Date modified: 2026-08-17T07:26:02+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.